Drug treatment for attention-deficit/hyperactivity disorder and suicidal behaviour: Register based study

BMJ (Online)

Volumn 348, Issue , 2014, Pages

  Chen, Qi ^a   Sjölander, Arvid ^a   Runeson, Bo ^a   D'Onofrio, Brian M ^b   Lichtenstein, Paul ^a   Larsson, Henrik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE; N 06 BA 01; N 06 BA 02; N 06 BA 04; N 06 BA 09; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; BORDERLINE STATE; CAUSE OF DEATH; COMORBIDITY; CONDUCT DISORDER; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG ABUSE; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; SUICIDE ATTEMPT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; ADULT; AMPHETAMINE; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; MALE; METHYLPHENIDATE; MIDDLE AGED; PROPYLAMINES; REGISTRIES; SUICIDE; SWEDEN; YOUNG ADULT;

EID: 84902590390     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g3769     Document Type: Article

References (34)

1. Biederman J. Attention-deficit/hyperactivity disorder: a selective overview. Biol Psychiatry 2005;57:1215-20. (Pubitemid 40798537)
2. Greydanus DE, Pratt HD, Patel DR. Attention deficit hyperactivity disorder across the lifespan: the child, adolescent, and adult. Dis Mon 2007;53:70-131. (Pubitemid 46452595)
3. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007;164:942-8. (Pubitemid 46972911)
4. Biederman J, Petty CR, Monuteaux MC, Fried R, Byrne D, Mirto T, et al. Adult psychiatric outcomes of girls with attention deficit hyperactivity disorder: 11-year follow-up in a longitudinal case-control study. Am J Psychiatry 2010;167:409-17.
5. Zuvekas SH, Vitiello B. Stimulant medication use in children: a 12-year perspective. Am J Psychiatry 2012;169:160-6.
6. Hodgkins P, Sasane R, Meijer WM. Pharmacologic treatment of attention-deficit/hyperactivity disorder in children: incidence, prevalence, and treatment patterns in the Netherlands. Clin Ther 2011;33:188-203.
7. Zetterqvist J, Asherson P, Halldner L, Langstrom N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand 2013;128:70-7.
8. Findling RL. Evolution of the treatment of attention-deficit/ hyperactivity disorder in children: a review. Clin Ther 2008;30:942-57. (Pubitemid 351799870)
9. Greenhill L, Kollins S, Abikoff H, McCracken J, Riddle M, Swanson J, et al. Efficacy and safety of immediate-release methylphenidate treatment for preschoolers with ADHD. J Am Acad Child Adolesc Psychiatry 2006;45:1284-93. (Pubitemid 44665445)
10. Surman CB, Hammerness PG, Pion K, Faraone SV. Do stimulants improve functioning in adults with ADHD? A review of the literature. Eur Neuropsychopharmacol 2013;23:528-33.
11. Durell TM, Adler LA, Williams DW, Deldar A, McGough JJ, Glaser PE, et al. Atomoxetine treatment of attention-deficit/hyperactivity disorder in young adults with assessment of functional outcomes: a randomized, double-blind, placebo-controlled clinical trial. J Clin Psychopharmacol 2013;33:45-54.
12. Food and Drug Administration. Public health advisory: suicidal thinking in children and adolescents being treated with Strattera (atomoxetine). FDA, 2005.
13. Bangs ME, Tauscher-Wisniewski S, Polzer J, Zhang S, Acharya N, Desaiah D, et al. Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 2008;47:209-18. (Pubitemid 351158789)
14. McCarthy S, Cranswick N, Potts L, Taylor E, Wong IC. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf 2009;32:1089-96.
15. Bushe CJ, Savill NC. Systematic review of atomoxetine data in childhood and adolescent attention-deficit hyperactivity disorder 2009-2011: focus on clinical efficacy and safety. J Psychopharmacol 2014;28:204-11.
16. Vitiello B, Riddle MA, Greenhill LL, March JS, Levine J, Schachar RJ, et al. How can we improve the assessment of safety in child and adolescent psychopharmacology? J Am Acad Child Adolesc Psychiatry 2003;42:634-41. (Pubitemid 39625048)
17. Rawlins M. De testimonio: on the evidence for decisions about the use of therapeutic interventions. Lancet 2008;372:2152-61.
18. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012;13:138.
19. Langley K, Fowler T, Ford T, Thapar AK, van den Bree M, Harold G, et al. Adolescent clinical outcomes for young people with attention-deficit hyperactivity disorder. Br J Psychiatry 2010;196:235-40.
20. Allison PD. Fixed effects regression methods for longitudinal data using SAS. SAS Institute, 2005.
21. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish prescribed drug register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35. (Pubitemid 47180362)
22. Lichtenstein P, Halldner L, Zetterqvist J, Sjolander A, Serlachius E, Fazel S, et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012;367:2006-14.
23. Chang Z, Lichtenstein P, D'Onofrio BM, Sjolander A, Larsson H. Serious transport accidents in adults with attention-deficit/hyperactivity disorder and the effect of medication: a population-based study. JAMA Psychiatry 2014;71:319-25.
24. De Faire U, Friberg L, Lorich U, Lundman T. A validation of cause-of-death certification in 1,156 deaths. Acta Med Scand 1976;200:223-8.
25. Tidemalm D, Langstrom N, Lichtenstein P, Runeson B. Risk of suicide after suicide attempt according to coexisting psychiatric disorder: Swedish cohort study with long term follow-up. BMJ 2008;337:a2205.
26. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry 2010;71:754-63.
27. Mann JJ, Arango VA, Avenevoli S, Brent DA, Champagne FA, Clayton P, et al. Candidate endophenotypes for genetic studies of suicidal behavior. Biol Psychiatry 2009;65:556-63.
28. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am J Psychiatry 2000;157:816-8. (Pubitemid 30249663)
29. McGough JJ, Smalley SL, McCracken JT, Yang M, Del'Homme M, Lynn DE, et al. Psychiatric comorbidity in adult attention deficit hyperactivity disorder: findings from multiplex families. Am J Psychiatry 2005;162:1621-7. (Pubitemid 41318230)
30. Sokero TP, Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET. Prospective study of risk factors for attempted suicide among patients with DSM-IV major depressive disorder. Br J Psychiatry 2005;186:314-8. (Pubitemid 40524010)
31. Food and Drug Administration. Summary minutes of the September 13-14, 2004 Center for Drug Evaluation and Research Pharmachopharmacologic Drugs Advisory Committee and the FDA Pediatric Advisory Committee. FDA, 2005.
32. Asherson P, Adamou M, Bolea B, Muller U, Morua SD, Pitts M, et al. Is ADHD a valid diagnosis in adults? Yes. BMJ 2010;340:c549.
33. Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. BMJ 2010;340:c547.
34. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med 2006;36:159-65. (Pubitemid 43126140)